Summit Therapeutics Inc

NASDAQ:SMMT  
5.36
-0.07 (-1.29%)
5:14:28 PM EDT: $6.10 +0.74 (+13.81%)
Earnings Announcements

Summit Therapeutics Reports Cash, Cash Equivalents On December 31, 2020, Of $66.4 Mln Vs $63.8 Mln On December 31, 2019

Published: 03/17/2021 11:54 GMT
Summit Therapeutics Inc (SMMT) - Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020.
Summit Therapeutics Inc - Cash and Cash Equivalents on December 31, 2020, of $66.4 Million Compared to $63.8 Million on December 31, 2019.
Revenue is expected to be $4.41 Million
Adjusted EPS is expected to be -$0.17

Next Quarter Revenue Guidance is expected to be $4.45 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.